Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 1918 – November 2018

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) 50 mg/200 mg/25 mg film-coated tablets

Submission by Gilead Sciences Ltd

Recommendation of the All Wales Medicines Strategy Group

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is recommended as an option for restricted use within NHS Wales.

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is licensed for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is restricted for use to patients who are either unsuitable for or unable to tolerate dolutegravir/abacavir/lamivudine (Triumeq®).

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent to or lower than the WPAS price.

Additional note(s):

- bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) should be used in line with All Wales Guidance for HIV treatment.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3414), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.